188 related articles for article (PubMed ID: 36178902)
21. SDHC phaeochromocytoma and paraganglioma: A UK-wide case series.
Williams ST; Chatzikyriakou P; Carroll PV; McGowan BM; Velusamy A; White G; Obholzer R; Akker S; Tufton N; Casey RT; Maher ER; Park SM; Porteous M; Dyer R; Tan T; Wernig F; Brady AF; Kosicka-Slawinska M; Whitelaw BC; Dorkins H; Lalloo F; Brennan P; Carlow J; Martin R; Mitchell AL; Harrison R; Hawkes L; Newell-Price J; Kelsall A; Igbokwe R; Adlard J; Schirwani S; Davidson R; Morrison PJ; Chung TT; Bowles C; Izatt L
Clin Endocrinol (Oxf); 2022 Apr; 96(4):499-512. PubMed ID: 34558728
[TBL] [Abstract][Full Text] [Related]
22. Universal Germline Panel Testing for Individuals With Pheochromocytoma and Paraganglioma Produces High Diagnostic Yield.
Horton C; LaDuca H; Deckman A; Durda K; Jackson M; Richardson ME; Tian Y; Yussuf A; Jasperson K; Else T
J Clin Endocrinol Metab; 2022 Apr; 107(5):e1917-e1923. PubMed ID: 35026032
[TBL] [Abstract][Full Text] [Related]
23. Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency.
Richter S; Peitzsch M; Rapizzi E; Lenders JW; Qin N; de Cubas AA; Schiavi F; Rao JU; Beuschlein F; Quinkler M; Timmers HJ; Opocher G; Mannelli M; Pacak K; Robledo M; Eisenhofer G
J Clin Endocrinol Metab; 2014 Oct; 99(10):3903-11. PubMed ID: 25014000
[TBL] [Abstract][Full Text] [Related]
24. Value of Immunohistochemical Expression of Apelin, Succinate Dehydrogenase B, Chromogranin B, Human Epidermal Growth Factor Receptor-2, Contactin 4, and Succinyl-CoA Synthetase Subunit Beta in Differentiating Metastatic From Non-Metastatic Pheochromocytoma and Paraganglioma.
Wang Y; Chen D; Pang Y; Xu X; Guan X; Liu L
Front Endocrinol (Lausanne); 2022; 13():882906. PubMed ID: 35574028
[TBL] [Abstract][Full Text] [Related]
25. Molecular Alterations in Dog Pheochromocytomas and Paragangliomas.
Korpershoek E; Dieduksman DAER; Grinwis GCM; Day MJ; Reusch CE; Hilbe M; Fracassi F; Krol NMG; Uitterlinden AG; de Klein A; Eussen B; Stoop H; de Krijger RR; Galac S; Dinjens WNM
Cancers (Basel); 2019 Apr; 11(5):. PubMed ID: 31052272
[TBL] [Abstract][Full Text] [Related]
26. Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas.
Wallace PW; Conrad C; Brückmann S; Pang Y; Caleiras E; Murakami M; Korpershoek E; Zhuang Z; Rapizzi E; Kroiss M; Gudziol V; Timmers HJ; Mannelli M; Pietzsch J; Beuschlein F; Pacak K; Robledo M; Klink B; Peitzsch M; Gill AJ; Tischler AS; de Krijger RR; Papathomas T; Aust D; Eisenhofer G; Richter S
J Pathol; 2020 Aug; 251(4):378-387. PubMed ID: 32462735
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
[TBL] [Abstract][Full Text] [Related]
28. Genetic and Clinical Profiles of Pheochromocytoma and Paraganglioma: A Single Center Study.
Ma X; Li M; Tong A; Wang F; Cui Y; Zhang X; Zhang Y; Chen S; Li Y
Front Endocrinol (Lausanne); 2020; 11():574662. PubMed ID: 33362715
[TBL] [Abstract][Full Text] [Related]
29. Germline SUCLG2 Variants in Patients With Pheochromocytoma and Paraganglioma.
Hadrava Vanova K; Pang Y; Krobova L; Kraus M; Nahacka Z; Boukalova S; Pack SD; Zobalova R; Zhu J; Huynh TT; Jochmanova I; Uher O; Hubackova S; Dvorakova S; Garrett TJ; Ghayee HK; Wu X; Schuster B; Knapp PE; Frysak Z; Hartmann I; Nilubol N; Cerny J; Taieb D; Rohlena J; Neuzil J; Yang C; Pacak K
J Natl Cancer Inst; 2022 Jan; 114(1):130-138. PubMed ID: 34415331
[TBL] [Abstract][Full Text] [Related]
30. Risk assessment of maternally inherited SDHD paraganglioma and phaeochromocytoma.
Burnichon N; Mazzella JM; Drui D; Amar L; Bertherat J; Coupier I; Delemer B; Guilhem I; Herman P; Kerlan V; Tabarin A; Wion N; Lahlou-Laforet K; Favier J; Gimenez-Roqueplo AP
J Med Genet; 2017 Feb; 54(2):125-133. PubMed ID: 27856506
[TBL] [Abstract][Full Text] [Related]
31. Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD.
Ricketts CJ; Forman JR; Rattenberry E; Bradshaw N; Lalloo F; Izatt L; Cole TR; Armstrong R; Kumar VK; Morrison PJ; Atkinson AB; Douglas F; Ball SG; Cook J; Srirangalingam U; Killick P; Kirby G; Aylwin S; Woodward ER; Evans DG; Hodgson SV; Murday V; Chew SL; Connell JM; Blundell TL; Macdonald F; Maher ER
Hum Mutat; 2010 Jan; 31(1):41-51. PubMed ID: 19802898
[TBL] [Abstract][Full Text] [Related]
32. Primary Renal Paragangliomas and Renal Neoplasia Associated with Pheochromocytoma/Paraganglioma: Analysis of von Hippel-Lindau (VHL), Succinate Dehydrogenase (SDHX) and Transmembrane Protein 127 (TMEM127).
Gupta S; Zhang J; Milosevic D; Mills JR; Grebe SK; Smith SC; Erickson LA
Endocr Pathol; 2017 Sep; 28(3):253-268. PubMed ID: 28646318
[TBL] [Abstract][Full Text] [Related]
33. GIPC2 is an endocrine-specific tumor suppressor gene for both sporadic and hereditary tumors of RET- and SDHB-, but not VHL-associated clusters of pheochromocytoma/paraganglioma.
Dong Y; Huang Y; Fan C; Wang L; Zhang R; Li W; Guo Z; Wang D; Zheng Z
Cell Death Dis; 2021 May; 12(5):444. PubMed ID: 33947839
[TBL] [Abstract][Full Text] [Related]
34. Germline SDHB mutations are common in patients with apparently sporadic sympathetic paragangliomas.
Klein RD; Jin L; Rumilla K; Young WF; Lloyd RV
Diagn Mol Pathol; 2008 Jun; 17(2):94-100. PubMed ID: 18382370
[TBL] [Abstract][Full Text] [Related]
35. Increased expression of Nrf2 and elevated glucose uptake in pheochromocytoma and paraganglioma with SDHB gene mutation.
Kamai T; Murakami S; Arai K; Nishihara D; Uematsu T; Ishida K; Kijima T
BMC Cancer; 2022 Mar; 22(1):289. PubMed ID: 35300626
[TBL] [Abstract][Full Text] [Related]
36. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.
Mete O; Asa SL; Gill AJ; Kimura N; de Krijger RR; Tischler A
Endocr Pathol; 2022 Mar; 33(1):90-114. PubMed ID: 35285002
[TBL] [Abstract][Full Text] [Related]
37. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status.
Eisenhofer G; Lenders JW; Siegert G; Bornstein SR; Friberg P; Milosevic D; Mannelli M; Linehan WM; Adams K; Timmers HJ; Pacak K
Eur J Cancer; 2012 Jul; 48(11):1739-49. PubMed ID: 22036874
[TBL] [Abstract][Full Text] [Related]
38. Novel germline mutations in the SDHB and SDHD genes in Japanese pheochromocytomas.
Isobe K; Minowada S; Tatsuno I; Suzukawa K; Nissato S; Nanmoku T; Hara H; Yashiro T; Kawakami Y; Takekoshi K
Horm Res; 2007; 68(2):68-71. PubMed ID: 17308434
[TBL] [Abstract][Full Text] [Related]
39. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
[TBL] [Abstract][Full Text] [Related]
40. Characteristics of germline mutations in Korean patients with pheochromocytoma/paraganglioma.
Kim JH; Kim MJ; Kong SH; Kim SJ; Kang H; Shin CS; Park SS; Lee KE; Seong MW
J Med Genet; 2022 Jan; 59(1):56-64. PubMed ID: 33219105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
